BACKGROUND: In type 2 diabetes, a decrease in myocardial glucose uptake (MGU) may lower glucose oxidation and contribute to progression of chronic heart failure (CHF). However, it is unsettled whether CHF patients with prediabetes have abnormal MGU and myocardial blood flow (MBF) during normal physiological conditions. METHODS AND RESULTS: We studied 35 patients with CHF and reduced left ventricular ejections fraction (34 ± 9%) without overt T2D (mean HbA1c: 40 ± 4 mmol/mol) using echocardiography and quantitative measurements of MGU by 18F-FDG-PET and perfusion by 15O-H2O-PET. An oral glucose tolerance test (OGTT) was performed during the FDG-PET, which identified 17 patients with abnormal and 18 patients with normal glucometabolic response. Global MGU was higher in patients with normal OGTT response (0.31 ± 0.09 µmol/g/min) compared with patients with abnormal OGTT response (0.25 ± 0.09 µmol/g/min) (P = 0.05). MBF (P = 0.22) and myocardial flow reserve (MFR) (P = 0.83) were similar in the study groups. The reduced MGU in prediabetic patients was attributable to reduced MGU in viable myocardium with normal MFR (P < 0.001). CONCLUSION:CHF patients with prediabetes have reduced MGU in segments with preserved MFR as compared to CHF patients with normal glucose tolerance. Whether reversal of these myocardial abnormalities can improve outcome needs to be investigated in large-scale studies.
RCT Entities:
BACKGROUND: In type 2 diabetes, a decrease in myocardial glucose uptake (MGU) may lower glucose oxidation and contribute to progression of chronic heart failure (CHF). However, it is unsettled whether CHFpatients with prediabetes have abnormal MGU and myocardial blood flow (MBF) during normal physiological conditions. METHODS AND RESULTS: We studied 35 patients with CHF and reduced left ventricular ejections fraction (34 ± 9%) without overt T2D (mean HbA1c: 40 ± 4 mmol/mol) using echocardiography and quantitative measurements of MGU by 18F-FDG-PET and perfusion by 15O-H2O-PET. An oral glucose tolerance test (OGTT) was performed during the FDG-PET, which identified 17 patients with abnormal and 18 patients with normal glucometabolic response. Global MGU was higher in patients with normal OGTT response (0.31 ± 0.09 µmol/g/min) compared with patients with abnormal OGTT response (0.25 ± 0.09 µmol/g/min) (P = 0.05). MBF (P = 0.22) and myocardial flow reserve (MFR) (P = 0.83) were similar in the study groups. The reduced MGU in prediabeticpatients was attributable to reduced MGU in viable myocardium with normal MFR (P < 0.001). CONCLUSION:CHFpatients with prediabetes have reduced MGU in segments with preserved MFR as compared to CHFpatients with normal glucose tolerance. Whether reversal of these myocardial abnormalities can improve outcome needs to be investigated in large-scale studies.
Entities:
Keywords:
Heart failure; diabetes, type 2; metabolic syndrome; nuclear cardiology and PET
Authors: Ibrahim Danad; Valtteri Uusitalo; Tanja Kero; Antti Saraste; Pieter G Raijmakers; Adriaan A Lammertsma; Martijn W Heymans; Sami A Kajander; Mikko Pietilä; Stefan James; Jens Sörensen; Paul Knaapen; Juhani Knuuti Journal: J Am Coll Cardiol Date: 2014-10-07 Impact factor: 24.094
Authors: Hanne M Søndergaard; Morten Bøttcher; Mette Marie Madsen; Ole Schmitz; Søren B Hansen; Torsten T Nielsen; Hans Erik Bøtker Journal: J Clin Endocrinol Metab Date: 2006-09-19 Impact factor: 5.958
Authors: M J Knuuti; M Mäki; H Yki-Järvinen; L M Voipio-Pulkki; R Härkönen; M Haaparanta; P Nuutila Journal: J Mol Cell Cardiol Date: 1995-07 Impact factor: 5.000
Authors: T Utriainen; T Takala; M Luotolahti; T Rönnemaa; H Laine; U Ruotsalainen; M Haaparanta; P Nuutila; H Yki-Järvinen Journal: Diabetologia Date: 1998-05 Impact factor: 10.122
Authors: Paul Knaapen; Ronald Boellaard; Marco J W Götte; Pieter A Dijkmans; Linda M C van Campen; Carel C de Cock; Gert Luurtsema; Cees A Visser; Adriaan A Lammertsma; Frans C Visser Journal: J Nucl Med Date: 2004-08 Impact factor: 10.057
Authors: David P Dutka; Michael Pitt; Domenico Pagano; Marco Mongillo; David Gathercole; Robert S Bonser; Paolo G Camici Journal: J Am Coll Cardiol Date: 2006-12-05 Impact factor: 24.094
Authors: Lars P Tolbod; Maria M Nielsen; Bodil G Pedersen; Søren Høyer; Hendrik J Harms; Michael Borre; Per Borghammer; Kirsten Bouchelouche; Jørgen Frøkiær; Jens Sørensen Journal: Am J Nucl Med Mol Imaging Date: 2018-10-20
Authors: Roni Nielsen; Anders Jorsal; Peter Iversen; Lars Poulsen Tolbod; Kirsten Bouchelouche; Jens Sørensen; Hendrik Johannes Harms; Allan Flyvbjerg; Lise Tarnow; Caroline Kistorp; Ida Gustafsson; Hans Erik Bøtker; Henrik Wiggers Journal: J Nucl Cardiol Date: 2017-08-02 Impact factor: 5.952
Authors: Elena Succurro; Patrizia Vizza; Annalisa Papa; Francesco Cicone; Giuseppe Monea; Giuseppe Tradigo; Teresa Vanessa Fiorentino; Maria Perticone; Pietro Hiram Guzzi; Angela Sciacqua; Francesco Andreozzi; Pierangelo Veltri; Giuseppe Lucio Cascini; Giorgio Sesti Journal: Front Cardiovasc Med Date: 2022-06-29
Authors: João Sérgio Neves; Simon Correa; Rute Baeta Baptista; Miguel Bigotte Vieira; Sushrut S Waikar; Finnian R Mc Causland Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958
Authors: Mona S Hansen; Asger Andersen; Lars P Tolbod; Nils H Hansson; Roni Nielsen; Anton Vonk-Noordegraaf; Jens Erik Nielsen-Kudsk Journal: Pulm Circ Date: 2017-11-03 Impact factor: 3.017
Authors: Karin Rådholm; Gemma Figtree; Vlado Perkovic; Scott D Solomon; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Terrance D Barrett; Wayne Shaw; Mehul Desai; David R Matthews; Bruce Neal Journal: Circulation Date: 2018-07-31 Impact factor: 29.690